🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. Rivaroxaban 2.5 mg

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Acute Coronary Syndrome

    phase 3 small molecule completed

    1 trial

  2. RoActemra 20 mg/mL concentrate for solution for infusion, Tofidence 20 mg/mL concentrate for solution for infusion, Avtozma 20 mg/mL concentrate for solution for infusion., SODIUM CHLORIDE, Tyenne 20 mg/ml concentrate for solution for infusion

    Pari Pharma GmbH

    Chondrocalcinosis

    phase 3 small molecule active

    1 trial

  3. Ropeginterferon alfa-2b

    PharmaEssentia

    Primary Myelofibrosis

    phase 3 mab active

    1 trial

  4. Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, -

    Lacuna Pharma Pty Ltd

    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)

    phase 3 small molecule active

    1 trial

  5. Rucaparib

    pharmaand GmbH

    Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  6. Ruxolitinib

    Novartis Pharmaceuticals

    Polycythemia Vera

    phase 3 small molecule completed

    1 trial

  7. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Super-refractory Status Epilepticus

    phase 3 small molecule completed

    2 trials

  8. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Huntington's Disease

    phase 3 small molecule terminated

    2 trials

  9. SAMYR 400 mg compresse gastroresistenti, Samyr placebo (same excipient as SAMYR)

    Mylan Pharma UK

    Major Depression Disorder

    phase 3 small molecule active

    1 trial

  10. SARCLISA 20mg/mL concentrate for solution for infusion., Iclusig 15 mg film-coated tablets, SARCLISA 20mg/mL concentrate for solution for infusion., BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion.

    Pari Pharma GmbH

    Patients aged 18-65 years old with newly diagnosed previously untreated ALL or T-LL.

    phase 3 small molecule active

    1 trial

  11. SARS-CoV-2 mRNA Vaccine

    Biotech Pharmaceutical Co.,

    COVID-19

    phase 3 mab active

    1 trial

  12. SD-809

    Teva Pharma GmbH

    Tardive Dyskinesia

    phase 3 small molecule completed

    3 trials

  13. SD-809

    Teva Pharma GmbH

    Chorea

    phase 3 small molecule completed

    1 trial

  14. SD-809

    Teva Pharma GmbH

    Chorea Associated With Huntington Disease

    phase 3 small molecule completed

    1 trial

  15. SECUKINUMAB

    Novartis Pharmaceuticals

    Polymyalgia Rheumatica

    phase 3 small molecule active

    1 trial

  16. SEG101

    Novartis Pharmaceuticals

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  17. SODIUM CHLORIDE, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Pari Pharma GmbH

    HPV vaccine

    phase 3 small molecule active

    1 trial

  18. SODIUM CHLORIDE, HYDROCORTISONE UPJOHN 100 mg, préparation injectable, Placebo of hydrocortisone 100 mg, Reverpleg 40 U.I./2 ml solution à diluer pour perfusion

    Pari Pharma GmbH

    Adult cardiac arrest patients with sustained ROSC and hemodynamic failure due to post-resuscitation syndrome

    phase 3 small molecule active

    1 trial

  19. SODIUM CHLORIDE, Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe.

    Pari Pharma GmbH

    PEDIATRIC ACUTE MYOCARDITIS

    phase 3 small molecule active

    1 trial

  20. SODIUM CHLORIDE, LEVETIRACETAM VIATRIS 100 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    Adult ICU patients with septic shock

    phase 3 small molecule active

    1 trial

  21. SODIUM CHLORIDE, ROPIVACAINE

    Pari Pharma GmbH

    Cancer surgery

    phase 3 small molecule active

    1 trial

  22. SODIUM CHLORIDE, Truxima 500 mg concentrate for solution for infusion

    Pari Pharma GmbH

    Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment

    phase 3 small molecule active

    1 trial

  23. SODIUM CHLORIDE, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  24. SODIUM CHLORIDE, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor), VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease (TED)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources